EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and clinical activity of the experimental
drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination
with irinotecan and cetuximab in K-ras wildtype metastatic colorectal cancer patients.